-
Mashup Score: 0DOACs Reduce Dementia Risk vs Warfarin in A-Fib - Psychiatry Advisor - 7 month(s) ago
For patients with atrial fibrillation (AF), the use of direct-acting oral anticoagulants (DOACs) significantly reduces dementia risk.
Source: www.psychiatryadvisor.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1NOACs vs. VKAs in TAVR patients with new-onset AFib: New meta-analysis examines key differences - 7 month(s) ago
The biggest differences between the two treatment options were major bleeding events and all-cause mortality. There was no significant difference when it came to stroke risk.
Source: cardiovascularbusiness.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#NOAC use is linked with less major bleeding events & deaths than VKAs when treating patients with new-onset #AFib after #TAVR, new research indicates. https://t.co/Zgh5nIac9v @CardioBusiness @byMichaelWalter
-
-
Mashup Score: 0DOACs Reduce Dementia Risk in Asian AFib Patients Compared to Traditional Blood Thinners - American College of Cardiology - 8 month(s) ago
Contact: Katie Glenn, kglenn@acc.org, The use of direct oral anticoagulants (DOACs) was associated with a reduction in dementia risk compared to traditional blood thinners — like warfarin — in atrial fibrillation patients, particularly in Asian patients. According to a study published today in JACC: Asia, this benefit may reverse with increased age and necessitates further follow-up study. “Asian patients are more likely to be sensitive to vitamin K antagonism, which puts them at high risk for bleeding
Source: www.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
DOAC use is associated with a reduced dementia risk compared to traditional blood thinners in #AFib patients, particularly in Asian patients. According to a #JACCAsia study, this benefit may reverse with increased age. Read more: https://t.co/b4UzKWtdkx #NOAC https://t.co/H7Bu5EKTzy
-
-
Mashup Score: 6Switching From VKA to NOAC in Frail Patients With AF: Frail-AF Trial - American College of Cardiology - 8 month(s) ago
Geoffrey D. Barnes, MD, MSc, FACC
Source: www.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Q: Should frail patients w/ #AFib be switched from a vitamin K antagonist (VKA) over to a #NOAC? A: Older, frail patients w/ AFib experienced ⬆️ bleeding when they switched from VKA to NOAC therapy rather than staying on VKA therapy. Read more here! 👇 https://t.co/WVMAw7naI2
-
-
Mashup Score: 0Impact of treatment adherence on the effectiveness and safety of oral anticoagulants in patients with atrial fibrillation: a retrospective cohort study - 12 month(s) ago
AbstractAims. The impact of adherence to oral anticoagulation has not been reported in terms of absolute risk, which would enhance patients’ understanding and t
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet-
The relevance of closely adhering to oral anticoagulation in #AFib – a retrospective cohort study on >80k patients in https://t.co/40Fjmmvxhb #EHJQCCO #Anticoag #NOAC @cpgale3 @diogoasantosfer @adamtimmis https://t.co/wk96AyP2aM
-
-
Mashup Score: 19
AbstractAims. Data on non-vitamin K antagonist oral anticoagulants (NOACs) use in patients with atrial fibrillation (AF) and frailty are scarce. Therefore, the
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Impact of frailty on the effectiveness & safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study #AFib #NOAC #frailty #EHJQCCO https://t.co/c8bcAAwg8T
-
-
Mashup Score: 0Recommendation on the Nomenclature for Anticoagulants: Updated Communication from the ISTH SSC Subcommittee on the Control of Anticoagulation - 1 year(s) ago
Oral anticoagulation therapy has evolved beyond vitamin K antagonists to include oral direct thrombin inhibitors and factor Xa inhibitors. Collectively known as ‘direct oral anticoagulants’, this class of medications represents the current standard of care for the prevention and treatment of common thrombotic disorders, including atrial fibrillation and venous thromboembolism. Medications that…
Categories: Hematologists1, Latest HeadlinesTweet-
🚨Nouvelle reco @ISTH nomenclature des anticoagulants ❌ On ne dit toujours pas NACO #NOAC 😇 ❌ On ne peut plus dire AOD #DOAC et on ne pourra pas dire AOD anti-FXIa 😢 ✅ Anti-Xa oral ✅ Anti-FXIa oral @GBarnesMD @LanaCastellucci @CukerMd https://t.co/offqTJw1gh https://t.co/dNdJtKQZCi
-
-
Mashup Score: 0
Researchers sought to compare the safety and efficacy of direct oral anticoagulants with vitamin-K antagonists in patients with thrombotic antiphospholipid syndrome.
Source: Rheumatology AdvisorCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Compared with those who received VKAs, patients with thrombotic antiphospholipid syndrome who received DOACs could have an increased risk of arterial thrombosis, a #JACC study found. Get the details in @RheumAdvisor: https://t.co/34RAksLuhv #NOAC
-
-
Mashup Score: 2
Researchers sought to compare the safety and efficacy of direct oral anticoagulants with vitamin-K antagonists in patients with thrombotic antiphospholipid syndrome.
Source: The Cardiology AdvisorCategories: Cardiology News and Journals, Latest HeadlinesTweet-
According to a study in #JACC, patients w/ thrombotic antiphospholipid syndrome who receive #DOAC could have an increased risk for arterial thrombosis. Read more about the new findings in @CardioAdvisor: https://t.co/mMN0w7X9Dx #NOAC
-
-
Mashup Score: 0Edoxaban an ‘Appropriate Alternative’ to Standard-of-Care Anticoagulants for Thromboembolism Prevention in Children: Phase 3 Data - 1 year(s) ago
The direct oral anticoagulant (DOAC) edoxaban is a potential alternative mode of thromboprophylaxis in children with cardiac disease showing low rates of clinically relevant bleeding (CRB) and thrombo
Categories: Cardiology News and Journals, Latest HeadlinesTweet-
The #NOAC edoxaban could be an alternative mode of thromboprophylaxis in children w/ cardiac disease w/ low rates of CRB and thromboembolism, according to the results of the ENNOBLE-ATE trial in #JACC. Find out more in @CRT_meeting: https://t.co/ILgWQ2aPJM #cvVTE #NOAC
-
Compared with warfarin, DOAC use significantly decreased dementia risk among #AFib patients, according to a systematic review & meta-analysis in #JACCAsia. @PsychiatryAdv reports on the findings here: https://t.co/uF5RLEMU0A #NOAC